Reports
Sale
Asia Pacific Viral Vector Manufacturing Market Size, Share: By Type: Adenoviral Vectors, Adeno-Associated Viral (AAV) Vectors, Lentiviral Vectors, Retroviral Vectors, Others; By Application: Gene Therapy, Cell Therapy, Vaccines; By Therapeutic Area: Oncological Disorders, Others; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Asia Pacific Viral Vector Manufacturing Market Outlook
The global viral vector manufacturing market size was valued at USD 2.6 billion in 2023, with Asia Pacific holding a significant market share. The market is driven by the increasing investment in the biotechnology and pharmaceutical sectors. It is expected to grow at a CAGR of 19.74% during the forecast period of 2024-2032, with the values likely to attain USD 13.5 billion by 2032.
Key Takeaways
- Viral vectors form a crucial component in gene therapy and vaccine manufacturing processes. The growing demand for gene therapies and vaccines to tackle the rising burden of infectious diseases and chronic diseases in the Asia Pacific region is expected to drive the market demand.
- One of the major Asia Pacific viral vector manufacturing market trends is the increased mergers and acquisitions among the key market players to share resources and expertise. In November 2023, Ajinomoto Co., Inc., a Japanese multinational biotechnology corporation, announced the acquisition of Forge Biologics Holdings, LLC in a deal worth USD 620 million to extend its capabilities in adeno-associated virus (AAV) and plasmid gene therapy manufacturing.
- In May 2023, CDMO Aurigene Pharmaceutical Services, a subsidiary of Indian multinational pharmaceutical company Dr. Reddy’s Laboratories, announced its plan to spend USD 40 million to build a production facility for viral vectors, therapeutic proteins, and antibodies. Such substantial investments to boost production capacity are poised to elevate market value.
Asia Pacific Viral Vector Manufacturing Market Analysis
Viral vectors act as an efficient gene delivery vehicle and are used to transfer genetic materials into cells. They are increasingly utilized by molecular biologists to manipulate a certain cell type or tissue to express therapeutic proteins. Viral vectors play a vital role in gene therapy and vaccine manufacturing processes due to their ability to transfer therapeutic genes or antigens into target cells. The growing demand for gene therapies and vaccines to tackle the rising burden of infectious diseases and chronic diseases is expected to drive the Asia Pacific viral vector manufacturing market growth in the forecast period.
One of the major market trends is the rising mergers and acquisitions among the key market players to share resources and expertise. In November 2023, Ajinomoto Co., Inc., a Japanese multinational food and biotechnology corporation, announced the acquisition of Forge Biologics Holdings, LLC (a viral vector and plasmid CDMO) in a deal worth USD 620 million to extend its capabilities in adeno-associated virus (AAV) and plasmid gene therapy manufacturing. The agreement will strengthen Ajinomoto’s position as a contract development and manufacturing organization (CDMO) as well as diversify its portfolio of services for gene and cell therapy clients. The transaction was completed in December 2023 . The rise in such strategic partnerships is expected to bolster the Asia Pacific viral vector manufacturing market share in the coming years.
In Asia Pacific, several leading companies are actively investing in the expansion of their production capacities. In May 2023, a leading contract research, development, and manufacturing organization (CDMO) Aurigene Pharmaceutical Services, a subsidiary of Indian multinational pharmaceutical company Dr. Reddy’s Laboratories, announced its plan to spend USD 40 million to build a production facility for viral vectors, therapeutic proteins, and antibodies, with the aim to offer integrated services from clinical research to commercial manufacturing for small and large molecules. The facility will be constructed at a biotech park in Hyderabad (India) called Genome Valley and is expected to be fully operational by the first half of 2024. Such substantial investments to boost production capacity are poised to elevate market value.
Asia Pacific Viral Vector Manufacturing Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
| Market Breakup | Categories |
| Type | Adenoviral Vectors, Adeno-Associated Viral (AAV) Vectors, Lentiviral Vectors, Retroviral Vectors, Others |
| Application | Gene Therapy, Cell Therapy, Vaccines |
| Therapeutic Area | Oncological Disorders, Neurological Disorders, Metabolic Disorders, Immunological Disorders, Others |
| End User | Research Organizations, Biotech and Pharmaceutical Companies, Others |
| Country | China, Japan, India, ASEAN, Australia, Others |
Asia Pacific Viral Vector Manufacturing Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Thermo Fisher Scientific
- Merck KGaA
- F. Hoffmann-La Roche AG
- Cobra Biologics
- VGXI, Inc.
- Kolon Life Science
- FUJIFILM Diosynth Biotechnologies
- Virovek
- Yposkesi
- Batavia Biosciences
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Application |
|
| Breakup by Therapeutic Area |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Asia Pacific Viral Vector Manufacturing Market Overview
3.1 Asia Pacific Viral Vector Manufacturing Market Historical Value (2017-2023)
3.2 Asia Pacific Viral Vector Manufacturing Market Forecast Value (2024-2032)
4 Asia Pacific Viral Vector Manufacturing Market Landscape*
4.1 Asia Pacific Viral Vector Manufacturing: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Asia Pacific Viral Vector Manufacturing: Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Technology
5 Asia Pacific Viral Vector Manufacturing Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Asia Pacific Viral Vector Manufacturing Market Segmentation (2017-2032)
6.1 Asia Pacific Viral Vector Manufacturing Market (2017-2032) by Type
6.1.1 Market Overview
6.1.2 Adenoviral Vectors
6.1.3 Adeno-Associated Viral (AAV) Vectors
6.1.4 Lentiviral Vectors
6.1.5 Retroviral Vectors
6.1.6 Others
6.2 Asia Pacific Viral Vector Manufacturing Market (2017-2032) by Application
6.2.1 Market Overview
6.2.2 Gene Therapy
6.2.3 Cell Therapy
6.2.4 Vaccines
6.3 Asia Pacific Viral Vector Manufacturing Market (2017-2032) by Therapeutic Area
6.3.1 Market Overview
6.3.2 Oncological Disorders
6.3.3 Neurological Disorders
6.3.4 Metabolic Disorders
6.3.5 Immunological Disorders
6.3.6 Others
6.4 Asia Pacific Viral Vector Manufacturing Market (2017-2032) by End User
6.4.1 Market Overview
6.4.2 Research Organizations
6.4.3 Biotech and Pharmaceutical Companies
6.4.4 Others
6.5 Asia Pacific Viral Vector Manufacturing Market (2017-2032) by Country
6.5.1 Market Overview
6.5.2 China
6.5.3 Japan
6.5.4 India
6.5.5 ASEAN
6.5.6 Australia
6.5.7 Others
7 China Viral Vector Manufacturing Market (2017-2032)
7.1 China Viral Vector Manufacturing Market (2017-2032) by Type
7.1.1 Market Overview
7.1.2 Adenoviral Vectors
7.1.3 Adeno-Associated Viral (AAV) Vectors
7.1.4 Lentiviral Vectors
7.1.5 Retroviral Vectors
7.1.6 Others
7.2 China Viral Vector Manufacturing Market (2017-2032) by Application
7.2.1 Market Overview
7.2.2 Gene Therapy
7.2.3 Cell Therapy
7.2.4 Vaccines
7.3 China Viral Vector Manufacturing Market (2017-2032) by Therapeutic Area
7.3.1 Market Overview
7.3.2 Oncological Disorders
7.3.3 Neurological Disorders
7.3.4 Metabolic Disorders
7.3.5 Immunological Disorders
7.3.6 Others
8 Japan Viral Vector Manufacturing Market (2017-2032)
8.1 Japan Viral Vector Manufacturing Market (2017-2032) by Type
8.1.1 Market Overview
8.1.2 Adenoviral Vectors
8.1.3 Adeno-Associated Viral (AAV) Vectors
8.1.4 Lentiviral Vectors
8.1.5 Retroviral Vectors
8.1.6 Others
8.2 Japan Viral Vector Manufacturing Market (2017-2032) by Application
8.2.1 Market Overview
8.2.2 Gene Therapy
8.2.3 Cell Therapy
8.2.4 Vaccines
8.3 Japan Viral Vector Manufacturing Market (2017-2032) by Therapeutic Area
8.3.1 Market Overview
8.3.2 Oncological Disorders
8.3.3 Neurological Disorders
8.3.4 Metabolic Disorders
8.3.5 Immunological Disorders
8.3.6 Others
8.4 Japan Viral Vector Manufacturing Market (2017-2032) by End User
8.4.1 Market Overview
8.4.2 Research Organizations
8.4.3 Biotech and Pharmaceutical Companies
8.4.4 Others
9 India Viral Vector Manufacturing Market (2017-2032)
9.1 India Viral Vector Manufacturing Market (2017-2032) by Type
9.1.1 Market Overview
9.1.2 Adenoviral Vectors
9.1.3 Adeno-Associated Viral (AAV) Vectors
9.1.4 Lentiviral Vectors
9.1.5 Retroviral Vectors
9.1.6 Others
9.2 India Viral Vector Manufacturing Market (2017-2032) by Application
9.2.1 Market Overview
9.2.2 Gene Therapy
9.2.3 Cell Therapy
9.2.4 Vaccines
9.3 India Viral Vector Manufacturing Market (2017-2032) by Therapeutic Area
9.3.1 Market Overview
9.3.2 Oncological Disorders
9.3.3 Neurological Disorders
9.3.4 Metabolic Disorders
9.3.5 Immunological Disorders
9.3.6 Others
9.4 India Viral Vector Manufacturing Market (2017-2032) by End User
9.4.1 Market Overview
9.4.2 Research Organizations
9.4.3 Biotech and Pharmaceutical Companies
9.4.4 Others
10 ASEAN Viral Vector Manufacturing Market (2017-2032)
10.1 ASEAN Viral Vector Manufacturing Market (2017-2032) by Type
10.1.1 Market Overview
10.1.2 Adenoviral Vectors
10.1.3 Adeno-Associated Viral (AAV) Vectors
10.1.4 Lentiviral Vectors
10.1.5 Retroviral Vectors
10.1.6 Others
10.2 ASEAN Viral Vector Manufacturing Market (2017-2032) by Application
10.2.1 Market Overview
10.2.2 Gene Therapy
10.2.3 Cell Therapy
10.2.4 Vaccines
10.3 ASEAN Viral Vector Manufacturing Market (2017-2032) by Therapeutic Area
10.3.1 Market Overview
10.3.2 Oncological Disorders
10.3.3 Neurological Disorders
10.3.4 Metabolic Disorders
10.3.5 Immunological Disorders
10.3.6 Others
10.4 ASEAN Viral Vector Manufacturing Market (2017-2032) by End User
10.4.1 Market Overview
10.4.2 Research Organizations
10.4.3 Biotech and Pharmaceutical Companies
10.4.4 Others
11 Australia Viral Vector Manufacturing Market (2017-2032)
11.1 Australia Viral Vector Manufacturing Market (2017-2032) by Type
11.1.1 Market Overview
11.1.2 Adenoviral Vectors
11.1.3 Adeno-Associated Viral (AAV) Vectors
11.1.4 Lentiviral Vectors
11.1.5 Retroviral Vectors
11.1.6 Others
11.2 Australia Viral Vector Manufacturing Market (2017-2032) by Application
11.2.1 Market Overview
11.2.2 Gene Therapy
11.2.3 Cell Therapy
11.2.4 Vaccines
11.3 Australia Viral Vector Manufacturing Market (2017-2032) by Therapeutic Area
11.3.1 Market Overview
11.3.2 Oncological Disorders
11.3.3 Neurological Disorders
11.3.4 Metabolic Disorders
11.3.5 Immunological Disorders
11.3.6 Others
11.4 Australia Viral Vector Manufacturing Market (2017-2032) by End User
11.4.1 Market Overview
11.4.2 Research Organizations
11.4.3 Biotech and Pharmaceutical Companies
11.4.4 Others
12 Others Regulatory Framework
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication Year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by Year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by Departments
14.7 Analysis by Recipient Organization
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Market Share by Top 5 Companies
17.2 Thermo Fisher Scientific
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Merck KGaA
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 F. Hoffmann-La Roche AG
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Cobra Biologics
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 VGXI, Inc.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Kolon Life Science
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 FUJIFILM Diosynth Biotechnologies
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Virovek
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Yposkesi
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Batavia Biosciences
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
18 Asia Pacific Viral Vector Manufacturing Market – Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The Asia Pacific viral vector manufacturing market is expected to be driven by the rising demand for the global viral vector manufacturing market, which is anticipated to grow at a CAGR of 19.74% during the forecast period of 2024-2032 and is likely to reach a market value of USD 13.5 billion by 2032.
The rising emphasis on the advancement of gene therapies and vaccines is fuelling the demand for the market.
One of the significant trends in the market is the increased mergers and acquisitions among the key market players to share resources and expertise. In November 2023, Ajinomoto Co., Inc., a Japanese multinational biotechnology corporation, announced the acquisition of Forge Biologics Holdings, LLC in a deal worth USD 620 million to extend its capabilities in adeno-associated virus (AAV) and plasmid gene therapy manufacturing.
Based on the type, the market is segmented into adenoviral vectors, adeno-associated viral (AAV) vectors, lentiviral vectors, and retroviral vectors, among others.
By therapeutic area, the market is divided into oncological disorders, neurological disorders, metabolic disorders, and immunological disorders, among others.
End users of the market are research organizations, biotech, and pharmaceutical companies, among others.
Major applications of viral vector manufacturing include gene therapy, cell therapy, and vaccines.
The market segmentation by countries includes China, Japan, India, ASEAN, and Australia, among others.
The key players in the market are Thermo Fisher Scientific, Merck KGaA, F. Hoffmann-La Roche AG, Cobra Biologics, VGXI, Inc., Kolon Life Science, FUJIFILM Diosynth Biotechnologies, Virovek, Yposkesi, and Batavia Biosciences.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2639
$2399
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 4399
$3999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 5829
$5299
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 6929
$6299
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER